Explore every episode of the podcast LifeSci Continuum with Bill Schick
Dive into the complete episode list for LifeSci Continuum with Bill Schick . Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.
Rows per page:
50
1–39 of 39
Title
Pub. Date
Duration
Regulatory Consultants and What They Get Wrong | Thomas Moore, PhD
27 Feb 2026
00:30:47
You can’t outsource judgment, but you don’t have to do it alone. If you’re navigating go-to-market decisions in a regulated space, work with Bill through MESH as your fractional CMO.
Talk with Bill at MESH. https://meshagency.com/about-bill-schick/
About this episode: Early-stage medtech founders often treat regulatory strategy as a checklist item. That mistake can cost years, capital, and credibility. In this episode, I sit down with Thomas Moore, founder of PTL Solutions, to understand why regulatory strategy is actually a business roadmap and how founders can engage with it intelligently without outsourcing their judgment.
00:00 Defining Regulatory Strategy 01:13 Thomas Moore Background 02:23 Why Regulatory Strategy Is a Core Business Tool 05:41 The Problem With Checkbox Regulatory Thinking 08:49 When Regulatory Consultants Miss the Mark 10:58 Why Founders Must Stay Engaged in Regulatory Strategy 12:26 What Investors Look for in Regulatory Planning 14:25 Can Founders Build Their Own Regulatory Strategy 16:14 Where MedTech Teams Get Stuck 21:18 The Must Have Elements of a Strong Regulatory Strategy 25:56 Why Regulatory Strategy Is Not a Linear Process
Regulatory strategy is often framed as a compliance hurdle — something to outsource, check off, and move past. But as Thomas Moore, PhD explains, that mindset quietly introduces risk across the entire business.
With over two decades in medical device development, Thomas has seen what happens when founders receive a beautifully written regulatory document they can’t defend, explain, or adapt. In this conversation, he reframes regulatory strategy as a living roadmap — one that connects product design, clinical evidence, quality systems, investor confidence, and FDA credibility.
This episode is especially relevant for early-stage medtech founders navigating limited budgets, compressed timelines, and high stakes. Thomas shares why founders don’t need to do everything themselves — but why they can’t afford to be hands-off either. From pre-subs to predicate strategy to “spinning plates” across functions, this conversation gives founders language, structure, and confidence to engage regulators and consultants from a position of clarity.
If you’re building a regulated product and trying to move fast without stepping on landmines, this episode will help you think more clearly about where regulatory fits — and why it’s inseparable from business strategy.
🎧 Subscribe to LifeSci Continuum for founder-level conversations on commercialization, regulation, and building durable life-science companies. https://meshagency.com/about-bill-schick/
Prepare For What Investors & the FDA Are Really Looking For | Tim Looney
20 Feb 2026
00:26:00
Need investor traction now? Bring in a fractional CMO to package your story, de-risk your milestones, and turn Tim’s engineering plan into an investable go-to-market narrative. Let’s align tech, timeline, and TAM. Book a strategy call with Bill. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
Founder-friendly, investor-real talk. In his second visit to LSC, Tim Looney (Northeast Biomedical) explains how to turn prototypes into investor-ready products: DHF done right, phased engineering plans, avoiding “jam it through” FDA myths, and picking the right money. https://www.linkedin.com/in/tlooney/
00:00 Why do MedTech founders get stuck after early traction 03:15 What do investors actually want to see before funding 07:10 Why does skipping process slow FDA and fundraising 11:45 What documentation really matters for MedTech devices 16:40 How should founders think about de risking early 21:30 What makes a MedTech product truly investor ready
Investors aren’t funding your cool device—they’re underwriting your ability to de-risk it. In this episode, Tim Looney (President & CEO, Northeast Biomedical) returns, breaking down the investor lens for med-tech: show a credible timeline, a traceable design history file, and a stage-gated plan that prevents “surprise” testing at the eleventh hour.
We dig into DHF essentials, how to avoid endless prototyping, and why “let the FDA tell us what’s missing” is the slowest, riskiest strategy. Tim shares a standout success—an EU class III clearance in two weeks thanks to a meticulous dossier—and a cautionary tale where a buyer inherited gaps and had to backfill under FDA scrutiny.
We also talk capital: why the color of money matters, how to spot investors who add operational value, and the signaling power of ISO 13485 systems, external advisors, and documented learnings.
If you’re preparing for investors—or realizing you should have prepared earlier—connect with Bill. Translate conviction into execution-ready roadmaps and pressure-test investor fit before urgency takes over. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
#MedTech #RegulatoryStrategy #InvestorReadiness
De-Risk with the Right Partners at the Right Time | Greg Lange
11 Sep 2025
00:52:25
Partner sprawl stalling progress? A Fractional CMO prioritizes what moves revenue now. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
Connect with Greg Lange https://www.linkedin.com/in/greg-lange-70bab04/
Early-stage medtech moves faster with the right partners. Greg Lange (Symbex) shares how to de-risk early, pick partners you can trust, and keep product + commercialization in lockstep. We cover founder archetypes, when to bring in reg/reimbursement, and the operating cadence that avoids “beautiful dead ends.”
00:00 – Who’s Greg & what Symbex does — design + commercialization under one roof 03:00 – Why partnerships matter — big-co vs startup dynamics; treat partners like partners 08:30 – The Maine case — MVP first, then V2; commercialization before “perfect” 13:30 – Founder archetypes — clinician, engineer, entrepreneur; typical misses and how to cover them 20:00 – When to bring in experts — reg, reimbursement, competitive scan; sprint without blinders 27:30 – Partner-first strategy — recruiting talent & capital by selling the vision early 33:00 – How to choose partners — trust signals, communication, no-surprises rule, say-no credibility 40:00 – Requirements & communication — MV-requirements, cadence, shared dashboards 46:00 – Budget & burn — share constraints, co-scope the work, optimize for speed-to-learning 50:00 – Three practical tips — align on mission, quarter-by-quarter deliverables, treat partners like key hires
Founder Field Manual: Three Moves That Save You Months
1) Start With the Story, Not the Spec. Before you sprint into building, write the one-page vision that explains why this exists, who it’s for, and how it wins. Share it with three people who would buy, use, or fund it and ask, “What’s missing?” This gives partners a north star, helps you say no to shiny objects, and turns early collaborators into advocates—because they can see where you’re going and how they fit.
2) De-Risk in Days, Not Quarters. Run a “week-one gauntlet”: a quick regulatory path read, a reimbursement/payor sanity check, and a 10-call voice-of-customer sprint. You’re not seeking perfection—just red-flag hunting. If a pathway, payment, or workflow blocker pops, pivot your scope now (MVP to masterpiece). This keeps burn pointed at validation instead of vanity, and it arms you with credible evidence when you talk to investors.
3) Choose Partners Like Co-Founders. Don’t outsource and hope—co-build and verify. Use a minimum viable requirements doc (one page is fine) and a no-surprises cadence (weekly 30-min sync + transparent task board). Favor partners who push back with alternatives (“no, and here’s the path”) over order-takers. Share your constraints—including budget—so they can design scope that actually ships. Trust, speed, and clear accountability beat rock-star resumes every time. Founder energy is real—but so are bottlenecks. Greg Lange, President & CEO at Symbex, breaks down how early-stage teams can use partnerships to de-risk, shorten timelines, and build products the market will actually buy. We cover founder archetypes (clinician, engineer, entrepreneur), when to bring in regulatory/reimbursement, what a “good partner” looks like, and why sharing your budget is a trust signal—not a weakness.
#MedTech #Partnerships #Startup
The Productivity Playbook for Biotech Leaders | Katalin Szegner
10 Sep 2025
00:52:13
Stuck in gridlock? Learn how a Fractional CMO can transform misalignment into momentum. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
Connect with Bill: https://www.linkedin.com/in/founderandcdo/
Connect with Kata: https://www.linkedin.com/in/katalinszegner/
Biotech product leader Katalin “Kata” Szegner shares how to replace meeting chaos with structure: silent ideation, equal airtime, clear decision ownership, and customer-centric differentiation. We cover ending gridlock, aligning R&D with commercial, and making workshops produce real decisions—not more meetings.
00:00:00 Intro 00:01:57 Meet Kata, Teacher to Project Manager in Biotech 00:02:56 Teaching skills that supercharge product teams 00:08:12 Where misalignment starts (R&D vs. commercial) 00:10:58 Founders vs Customers, Ambition vs Traction, Growth vs. Compliance 00:16:32 Equal voices: silent ideation, dot voting, decision roles 00:26:12 Case: 18-month stall solved in hours by surfacing hidden insight 00:36:32 Workshop setup: boundaries, objectives, timeboxing, decision maker present 00:40:00 How to Set Boundaries 00:42:22 Visual frameworks that unlock clarity (Hot Air Balloon, etc.) 00:46:42 Foundation sprint & customer-centric differentiation 00:50:00 Marketing early: jobs-to-be-done and VOC as strategy, not afterthought 00:52:12 Wrap: courage, cadence, and the value of a neutral facilitator
Today’s guest, Katalin “Kata” Szegner, moved from the biology classroom to leading complex biotech products—and brought the secret with her: it’s not “clarity first,” it’s connection first. Kata shows how misalignment takes hold (founders’ vision vs. feasibility, R&D rigor vs. commercial urgency) and how to replace it with lightweight structure.
We unpack silent ideation to hear the quiet 80%, dot voting to separate ideas from egos, and clear decision ownership so meetings end in movement. Kata shares a vivid example where a team spun for 18 months—until a structured session surfaced the missing technical truth and unlocked a fix in hours.
You’ll get a simple toolkit for workshops that work: set boundaries (phones down, time blocked), publish the objective, assign the decider, and use visual frameworks (e.g., Hot Air Balloon) to make complex tradeoffs tangible. We close on customer-centric differentiation and why marketing must be present from phase zero—not as an afterthought once the science is “done.”
From Gridlock to Go: 3 Alignment Fixes Pros Miss
Equalize the room with silent ideation. Kick off key discussions heads-down: 60–120 seconds of quiet writing on cards or stickies before anyone speaks. Then de-dupe, group, and dot-vote. This prevents “first-voice contamination,” surfaces the 80% who rarely talk, and gives you a ranked input set to work from.
Put a decider in the room—explicitly. Name the decision-maker up front and confirm their attendance for the full session. Timebox each segment, finish with a single documented decision, owner, and next step. Set simple guardrails (no laptops/phones, full-day focus) so the group can actually decide, not just discuss.
Do the prework to remove surprises. Before the workshop, interview stakeholders, map who must be present (and influential absences), list known assumptions, and define success criteria. Bring 1–2 visual frameworks (e.g., Hot-Air Balloon) and a strawman/prototype to test the highest-risk assumption first. This turns the session into validation, not discovery.
Continue your founder’s journey with another episode: https://www.youtube.com/playlist?list=PLibD2fYYaAIISuFLmIXfzrh9_QgB9E2u8
#Biotech #ProductManagement #MedTech
De-Risk and Master Phase Zero | Aaron Joseph & Russ Singleton
01 Sep 2025
00:51:42
Work with Bill: https://meshagency.com/lets-connect/
- Aaron Joseph https://www.linkedin.com/in/ajosephprofile/ - Russ Singleton https://www.linkedin.com/in/russellsingleton/
Here’s the link to their blog series: https://www.mpo-mag.com/author/russell-m-singletonrodmaneditors-mpo-com/
00:00 Introduction and guest bios (Aaron Joseph & Russ Singleton) 01:40 Backgrounds in medtech, compliance, and product development 03:40 What is Phase Zero in medical device development? 05:30 Why skipping Phase Zero leads to compliance & product failures 07:00 The physician-inventor dilemma: “I am my own customer” 10:30 Early adopters vs. mainstream market realities 13:00 Phase Zero on steroids: knowledge-building, risk reduction, and planning 19:00 Success through feasibility checks, fail-fast pivots, and market validation 25:00 Jobs-to-Be-Done, customer discovery, and avoiding founder bias 41:00 Practical advice for clinicians and teams starting innovation journeys 50:30 Final thoughts: passion, customer focus, and long-term impact
Medtech veterans and co-authors/thought leaders Aaron Joseph (Sunstone Pilot) and Russ Singleton unpack “phase zero on steroids”—the disciplined, pre-development work that de-risks science, validates real jobs-to-be-done, and sets your regulatory and reimbursement strategy before you write a line of code. Expect war stories, practical frameworks, and the permission to cancel projects early (that’s a win).
Most early-stage device teams rush into development and end up paying for it in rework, delays, or regulatory dead ends. In this episode, I chat with Aaron Joseph—principal consultant at Sunstone Pilot—and Russ Singleton—results-driven medtech executive and company builder. Aaron and Russ show you how to run Phase Zero on Steroids.
Three Tactics to Make Your Phase 0 Worthwhile Russ and Aaron have three key takeaways for your med-tech journey pre-development, all with the promise of reducing headaches when executed properly.
Front-Load Truth, Not Features. Begin Phase Zero by naming the job-to-be-done in one plain sentence and testing it with a representative set of users—not just top-5% surgeons. Pair a market-ear with a technology-ear in every interview to capture both desirability and feasibility. Write down kill criteria (technical, clinical, regulatory, economic) you’ll honor. If you hit them, pivot or stop. Canceling early is a success that preserves runway.
Make Science a Workstream with Exit Gates. Treat unknowns like experiments: define the question, the method, the success threshold, and the next decision. Time-box these studies and document what you learn so results flow directly into design inputs. In parallel, map regulatory strategy (e.g., 510(k) vs PMA), evidence requirements (clinical/usability/electrical safety/sterilization), and reimbursement hypotheses. Often the fastest market path is a tight v1.0 with limited indications that establishes a regulatory baseline. Design for Adoption Across Four Buyers.
You’re not just convincing a clinician—you’re convincing a system. Quantify switching costs and plan proof that speaks to (1) the user, (2) the hospital/economic buyer, (3) the payer/reimbursement gate, and (4) internal champions. Build your go-to-market around early centers that match your first winning application, then expand indications. Keep Phase Zero lean but funded: small, passionate core team; targeted outside experts; a 5-page plan that a VC—or your own GM—can say yes to.
Want help turning messy early insights into a crisp strategy, message, and launch plan? Bring in a Fractional CMO. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
#MedTech #MedicalDevices #healthcareinnovation
Stop Assuming The Market Will Say Yes | Jack O’Callaghan
Follow Jack O’Callaghan - https://www.linkedin.com/in/jack-o-callaghan-5672636/
Founders don’t fail for lack of ideas—they fail for ignoring payers, regulators, and real user needs. Today I sit down with Jack O’Callaghan (Director, Business Development, Northeast Biomedical) about this very challenge. Jack explains why “build it and they will come” collapses in medtech. We get practical about payer and regulatory realities, user-needs documents, TAM fantasies, voice-of-customer, KOL strategies, and why v1.0 is never the finish line.
00:00 Why the system won’t say “yes” by default 01:27 Jack’s path: pharma → devices → engineering services 03:08 What Northeast Biomedical actually builds 04:20 Examples: reagent processor (goat blood for lateral flow), vision-guided robots, drug-delivery catheters 05:10 Where founders underestimate the journey 08:33 Reimbursement reality: enteral feeding example 12:11 You don’t sell to a person; you sell into a system 17:00 Medicine as art: implications for product design 22:56 TAM delusions and setting reachable targets 26:09 DoD “I just need to find the right person” myth 31:00 Time, bandwidth, and the cost of learning everything yourself 36:02 Prototypes, investors, and exit clarity 41:03 “I just need a distributor” (no, you don’t) 43:07 Start with user needs (engineering + commercial) 45:14 Garage prototypes and the laws of physics 47:22 Admit what you don’t know—then staff it
Three Moves That Shorten the Road to Adoption Be realistic and think about the entire product journey. Most founders pitch a giant TAM and assume clinicians will pull the product through. Replace that with a real adoption plan. Define the serviceable market you can actually reach in the first 12–24 months, by site type and procedure volume. Map the buying center for each site: the clinical champion, the economic buyer, supply chain, biomed, and IT. Tie your value to what each of them cares about. If your claim is time saved, translate it to minutes per case and the OR cost per minute. If you reduce complications, translate it to fewer readmissions and avoid penalties. Engage payers early to confirm coding, coverage, and payment so the business case survives first contact with reality.
Admit what you don’t know and hire it early. Speed comes from admitting what you do not know and buying the right help early. Before you touch CAD again, lock a one-page user needs document and a preliminary regulatory and reimbursement path. Do a quick freedom-to-operate check. In parallel, bring in fractional experts for regulatory, quality, reimbursement, clinical affairs, and product marketing. Their fees are small compared with the cost of delay or a redesign that shows up after your first animal lab. A class II pathway can reach into the tens of millions and beyond; every month you shave by parallelizing workstreams and avoiding rework is real money and earlier evidence.
Plan to learn fast rather than launch perfect. Treat version 1 as the instrument you use to collect voice-of-customer and usability data that informs version 2 and 3. Schedule bench, cadaver, or animal sessions and capture structured feedback. Build a small KOL council and put them on a cadence. Document changes, train on the procedure, and collect outcomes that quantify your promise in terms the system buys: OR minutes avoided, length of stay reduced, fewer transfers, fewer reoperations. Line those metrics up with your coding and payment story so clinical and financial value show up in the same frame.
If your deck still shows a massive TAM but you lack a sequenced GTM, bring in a fractional CMO to convert user needs and payer logic into a market-access plan that actually moves revenue: https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
#MedTech #MedicalDevices #Mark
Translate Complex Science into Memorable Messaging | Elizabeth Lumpkin
14 Aug 2025
00:42:32
Connect with Bill on LinkedIn: https://www.linkedin.com/in/founderandcdo/
Discover how an on-demand Fractional CMO can sharpen your story and accelerate growth—visit https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
00:00 Intro 02:30 Miscommunication in Medicine 06:40 Founders Miscommunication 11:35 Assumptions in Language 14:25 Identifying Your Audience 16:40 Communicating Painpoints & Needs 20:32 Credentialing 23:05 Founders Communicating to Customer 31:00 Methods for Sharing Ideas with your Founder 35:30 Trade Journal Ads 37:00 Problem vs Product 40:52 Avoiding Revolutionary Language 41:32 Advice for Founders
Medicine brims with life-saving innovation, yet audiences still tune out because the language feels alien. Today I sit down with Noel as she outlines a three-step playbook for breaking that cycle. First she shows how to pinpoint exactly who you are talking to and strip away insider shorthand that sabotages clarity. Next she demonstrates the power of storytelling—why a short patient vignette sticks long after a bullet list of specs. Finally she maps features to stakeholders’ true pain points, from clinicians starved for time to hospital CFOs bleeding cash on readmissions.
The result is messaging that earns trust, overcomes change resistance, and moves products off the brochure page and into everyday practice.
With that in mind, here are some recommendations to better connect with your audience.
Name the Listener, Tell the Story, Pinpoint the Pain
Start every project by writing a single sentence that defines exactly who you are talking to. A sentence like “We help over-worked oncology nurses reduce charting time” forces you to picture a real person, not a demographic blur. Once that sentence is on paper, read every headline, slide, and web page aloud using the words your audience would use in a hallway conversation. Terms that sail through an R-and-D meeting often stall when the same words land in a clinic lobby. If a phrase raises eyebrows or needs a footnote, swap it for something plainer before it leaves your desk.
Next, turn your glossary into a library of short stories. Replace abstract benefits with moments your audience can feel. “Reduces post-op hypothermia” is a statistic; “Your patient wakes up warm instead of shivering” is a scene everyone remembers. Collect these scenes in a living archive so your sales deck, social posts, and regulatory summaries draw from the same human moments. Familiar stories travel farther than flawless jargon, and they build the trust that complex data alone rarely earns. Finally, translate each feature into a tangible pain point. Show how shaving five minutes off an intubation saves two operating-room turnovers a day, or how a single avoided readmission keeps thirty thousand dollars in the hospital’s budget. When you frame benefits in time, money, or quality metrics that already keep stakeholders up at night, your pitch stops feeling like a nice-to-have and starts reading like an urgent line item.
Launching Healthtech Wearables in Hospitals | Shreya Divatia
27 Jun 2025
00:34:45
In this episode of LifeSci Continuum, I sit down with Shreya Divatia. Shreya has spent a decade rescuing med-tech programs from hidden failure points and turning “it works in the lab” into “it works on a 102-year-old patient with spotty Wi-Fi.”
Learn how I can help you buid a bridge between your business strategy and real growth as a Fractional Chief Marketing Officer. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
Timestamps: 00:00 Intro 01:30 Shreya’s Story & Experience 03:28 Shreya’s Unique Strength 04:13 Founder’s Blindspots 05:14 Wearable Med Device Case Study 08:50 Blindspots 13:17 Analysis of Wearable Med Device Case Study 15:34 Usablity & Consumer Assumptions 18:14 Case Study Solution 19:43 Learning from Failure 22:25 How to Identify the Right Target Audience 24:10 Voice of the Customer 25:00 The Value of Feedback 29:00 3 Tips for Product Marketing 33:42 Advice for Younger Self
She walks us through an ambitious but bumpy attempt to graft a consumer wearable onto a hospital software backbone—a mash-up that looked perfect on paper until Day 3, when every sensor declared itself “disconnected.”
Shreya unpacks why regulatory clearance is only the starting line, how to spot workflow landmines before nurses do, and the mind-shift founders need when hardware, software, and human factors collide inside real wards.
Three Overlooked Checks That Decide Whether Your Hospital Pilot Lives or Dies
Many founders race from first prototype to regulatory green light and assume the toughest hurdles are behind them. In reality the true test begins when a night-shift nurse clips your sensor to a patient and expects flawless data while juggling alarms, charting, and a shaky Wi-Fi network.
The steps that most teams skip are not glamorous pieces of science or elegant code. They are blunt reality checks that expose whether your device can survive the messy, unpredictable world of a hospital ward. Ignoring them does not merely delay a launch. It erodes staff trust, drains investor patience, and risks patient safety.
Running shadow trials on the actual unit rather than only in the engineering lab is your first safeguard. Hospital corridors bounce Bluetooth signals off metal carts, routers drop packets every time someone microwaves lunch, and vitals rounds happen when your entire dev team is asleep. A single overnight trial uncovers battery-drain patterns, latency spikes, and pairing failures that weeks of office testing never reveal.
The second safeguard is mapping every quiet stakeholder by role and watching how they naturally interact with your prototype. Certified nursing assistants reposition patients and tug on cords you labeled “do-not-pull.” Biomedical engineers dismantle housings for their mandatory weekly cleaning routine and expose boards you never coated for disinfectant.
Housekeeping staff unplug your access point because they need the outlet for a floor polisher. These improvised work-arounds are early warning signals. What breaks under their normal workflow will become the reason nurses refuse to wear your pager on their belts six months later, even if the chief medical officer loved your demo.
Finally, teams must separate “regulatory safe” from “workflow safe” in their timeline and budget. Passing IEC and FDA tests confirms electrical safety and basic performance, but it says nothing about whether the device keeps streaming when bandwidth drops, whether a clinician mistakes an antenna for a convenient handle, or whether alerts merge seamlessly into the hospital’s existing middleware.
Use an FCMO to Transform Marketing Waste into Full Throttle Growth
19 Jun 2025
00:34:45
In this episode of LifeSci Continuum, I sit down with Pete Tortorell, GM/Managing Director of Omni International (now Revvity).
Timestamps: 00:00 Intro 01:24 Pete’s Story 02:07 COVID19 Case Study 07:20 Good Marketing is Hard to Find 12:00 Working with MESH Interactive 13:32 Lead Generation 14:50 Measuring KPIs 17:20 The Value of a FCMO 24:30 Marketing Education 26:05 Marketing Competition 28:45 Traditional Marketing is Dead 31:15 Founder & CEO Advice
When 2020 erased half of Omni International’s revenue in a single month, Pete didn’t slash headcount—he rebuilt the business.
Join me as Pete traces Omni’s journey from a stand-alone sample-prep brand to a Revvity business unit that still owns its P&L and customer relationships. He recounts the 2020 free-fall when labs closed worldwide, the rapid collaboration with Georgia Tech that repositioned saliva testing, and the acquisition turbulence that followed.
Pete explains why he skipped agency “textbook” pitches and chose a fractional CMO who could challenge assumptions, and built a repeatable framework that any mid-market life-science company can copy to generate demand without hiring a dozen specialists.
Do you think your marketing investment is going to waste? Learn why Founders are turning to FCMOs: https://meshagency.com/for-founders/
Three Overlooked Fixes That Turn Marketing Spend Into Pipeline Growth Most early-stage companies assume a bigger marketing budget will automatically translate into qualified leads, yet the same dollars often vanish into tactics that look busy but move no revenue. The root causes usually hide in three places: unexamined spending, rigid staffing models, and content that talks instead of proves.
First, every life-science or med-device founder needs a single pane of glass for company health, marketing traction, and customer-service pulse.
First, hook your source-of-truth systems (ERP, CRM, and ticketing) to a lightweight BI tool—don’t custom-code; Zapier or native connectors will do. Second, agree on three to five metrics per area before you design anything; if it doesn’t guide a decision, kill it. Third, set automated alerts at the “uh-oh” thresholds so you react in hours, not quarters—think churn spike, lead-to-SQL drop, or NPS dip. Do that, and you’ve got a living cockpit that keeps the science moving and the money people smiling.
Second, think of senior marketing expertise as cloud infrastructure: rent it when you need it, scale it back when you do not, and keep permanent headcount focused on the science and customer support your brand is known for. Founders who insist on a full-time director before product-market fit end up paying executive salaries for work that could be handled fractionally (and at a fraction of the cost). A flexible model also brings in fresh perspective every quarter and prevents your message from calcifying around last year's tactics.
Finally, replace generic product copy with application stories authored by the scientists who actually use your products. Prospects trust peers who can say, “This homogenizer cut my sample-prep time by forty percent,” far more than they trust brochure language about “innovative design.” When real users explain the before and after of throughput, reproducibility, and budget impact, conversion rates climb and sales conversations start closer to the finish line. Marketing shifts from a push activity to proof that the tool already delivers in labs just like theirs.
Learn how I can help you grow your business as a Fractional Chief Marketing Officer. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
Turn Your Bench-Top Idea into a Reimbursable Diagnostic | Laurel Nelson
16 Jun 2025
00:43:46
In this episode of LifeSci Continuum, I sit down with Laurel Nelson (Founder, InnovexDx), who breaks down how diagnostics and life-science start-ups can actually commercialize when cash is tight and timelines keep slipping.
Learn how I can help you grow your business as a Fractional Chief Marketing Officer. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
Timestamps: 00:00 Intro 01:10 Laurel Nelson’s Career 02:50 Launching a Product with a Limited Budget 06:01 Common Founder Challenges 14:22 Founder Scientists vs Marketing 16:00 How to Build Credibility with Investors 21:15 Preparing a Good Idea for Commercialization 26:01 Phase Gate 28:26 How to Find Market Data 32:14 Market Access 35:25 Being Transparent with Investors 39:50 3 Tips for Founders 41:04 Wisdom for Younger Self
She explains why constant “lab tinkering” kills launch velocity, how a lightweight phase-gate process forces objective kill/keep decisions, and where founders routinely underrate market-access spending.
We also dig into her favorite “pressure-tests” for product-market fit, why external verification must precede scale, and how to recut the business case at every milestone so investors stay onside.
Three Commercial “Gotchas” That Sink More Lab-Startup Launches Than the Science Itself
Most first-time founders pour their energy into perfecting assay sensitivity or edge-case workflow hacks, yet overlook the far less glamorous forces that actually determine market uptake— reimbursement math, risk-gated execution, and supply-chain resilience. Laurel Nelson’s work with diagnostics start-ups shows the same three blind spots cropping up again and again, each capable of halving a valuation before anyone discovers an analytical bug.
Start with reimbursement, not with the prototype. The CPT or PLA code you intend to bill against—along with its evidence requirements and likely payment rate—quietly dictates half of your design envelope: sample-to-answer time, staff touch points, throughput thresholds, even consumable cost ceilings. Founders who “figure out coding later” end up redesigning hardware to hit margin, or worse, they head to market trapped under a price cap that investors immediately factor into a down-round.
Next, enforce micro phase-gates—even if that’s nothing more than three Google slides and a Slack channel. Moving an idea through quick feasibility, alpha verification, and an external beta test surfaces killer assumptions while the fixes are still cheap. These lightweight gates catch the moment a clinician says, “Great data, but my lab would never change this workflow,” before you’ve ordered production molds or spun up a $200 k validation study. They also give boards the proof points they need to keep financing flowing without funding every shiny R&D tangent.
Finally, lock dual-vendor coverage for every critical consumable as soon as verification passes. A single polymerase lot that fails QC can stall trials for months, derailing a Series A timeline and torching your credibility with early adopters. Qualifying at least two suppliers—complete with incoming QC specs—turns supply hiccups into routine purchase-order swaps and lets you scale when that first major hospital system says yes.
None of these moves are exciting science, and that’s the point. They remove the non-scientific landmines that so often explode after launch, allowing the real innovation to speak for itself—and to get paid.
In this episode of LifeSci Continuum, I sit down with Bill Kenney, Founder of MEET (My Expo & Event Team), to unpack why most life science and med device trade show strategies fail—and how to fix them.
Timestamps: 00:00 Intro 01:28 Bill Kenney’s Work in Bio-Tech 02:30 In-Person Inbound Marketing 03:20 How We Met 03:35 How to Get High Quality Leads at Tradeshows and Conferences 07:10 The Best Approach to Messaging at Tradeshow and Conferences 13:36 AIDA Framework 14:35 Communication Anecdote 15:40 Have a Conversation with your Customer 19:27 Identifying Quality Leads 27:26 Customer Density 31:56 Founders are Stretched Thin 35:00 How to Design your Tradeshow Booth 41:26 Positioning & Messaging in Life Science Marketing 44:37 When there is a Lack of Data 47:42 Final Takeaway
Bill works with international life science and medtech companies looking to break into the U.S. market and transform events—both regional and national.
We go deep on: Why casting a wide net leads to “prospect creep” and diluted messaging How to design your booth and message to attract only high-value prospects The importance of problem-first communication (not product features) Using smaller, local events as strategic proving grounds to test and optimize before big national shows.
How customer density drives repeatable sales models—and why most startups ignore this critical early move.
Bill brings a wealth of insight from years of helping companies sharpen their event strategy, align in-person sales and marketing around a shared goal, and stop wasting time chasing the wrong leads.
Some tips on standing out at your conference or show For founders and commercial leads looking to stand out on a crowded trade show floor and drive the right traffic to their booth, the winning combo is: interactive engagement, AI-powered tools, and a splash of unexpected delight. Here are a few expert-level ideas that go beyond the usual tchotchkes and posterboards:
1. AI-Powered Persona Match Quiz Set up a sleek iPad or touchscreen station at your booth where visitors can take a 1-minute interactive quiz:
"What kind of researcher/clinician/investor are you?" Use AI to match their responses to different solutions you offer—then hand them a personalized takeaway (PDF, print card, link to demo) that speaks directly to their use case or pain point.
2. Live ‘Problem Wall’ with Real-Time AI Ideation Dedicate part of your booth to a writable wall or digital board where attendees can post their biggest pain points. Behind the scenes, use GPT-based AI to generate potential ideas or reframed problem statements in real time.
3. Augmented Reality (AR) Demos with Immersive Layers Rather than handing someone a data sheet or trying to explain your tech on a static banner, use AR (through a phone or tablet) to let visitors overlay your product or system into their environment.
4. Post-Event AI Concierge Follow-Up Let booth visitors opt into a concierge-style AI follow-up. For example, after a scan or signup, they receive an email: "Hey, I saw you were interested in XYZ. Over the next 3 days, I’ll send you 3 short insights or case studies that might help."
5. Mini “Voice of the Industry” Video Booth Offer a quick video booth experience where attendees can record their thoughts on a specific industry challenge (30 sec max). Use AI transcription + summarization to compile a post-show “State of the Industry” montage or blog.
For deeper insights on life science and med device growth, check out my linkedin newsletter, Save Yourself. Subscribe on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7154518390324281344
For more specialized help with growth, check out my firm, Mesh. https://meshagency.com/
#LifeSciences #HealthcareInn
Tailor Your Pitch for VC | David Iannetta
23 Apr 2025
00:18:29
Connect with Dave Iannetta on Linkedin: https://www.linkedin.com/in/dave-iannetta/
Interested in getting 18+ Years of Cheat Codes, Perspective, and Tips for Surviving Marketing in Life Sciences and Medical Devices?
• Subscribe to Bill Schick’s Newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7154518390324281344
Or Connect with Bill directly on Linkedin https://www.linkedin.com/in/founderandcdo/
Timestamps: 00:00 Intro 00:55 Venture Capital Investors 03:09 Challenges of a Venture Investor Partnership 04:11 Building a Business Network to find Investors 05:00 The Key to Venture Investing: Clinical Validation 06:16 How to Build Credibility 07:45 Voice of the Customer 08:25 Major Risk for Life Science Companies 10:26 The Value of Building an Audience Before You Launch 11:49 Brand Building Case Study 13:54 Marketing Opportunities for Life Science Companies
About this Episode:
In part two of my conversation with seasoned marketing executive Dave Iannetta, we explore how life science and medtech companies must evolve their marketing strategy during the venture capital stage of funding. Unlike angel investors who often demand scientific granularity, VCs bring both capital and powerful networks—but expect startups to demonstrate growing market readiness, physician validation, and strategic focus.
Dave shares hard-earned lessons from his work in venture-backed firms, emphasizing that your messaging must shift from scientific promise to clinical credibility and commercial potential. We unpack the importance of engaging advisors early, not just as formal board members but as trusted text-message-level sounding boards. We also get into how continuous, informal feedback from KOLs and physician stakeholders strengthens your credibility with investors and sharpens your product roadmap.
Whether you're building your first advisory board or rethinking your investor pitch, this episode offers a blueprint for transforming market conversations into momentum—before your next funding milestone.
Featured Pro Tips:
One thing I’ve found while working as a Fractional Chief Marketing Officer for life science and medical device manufacturers that doesn’t get talked about enough is just how early you should start building relationships with your future KOLs. And I’m not talking about scheduling six-month advisory board meetings and waiting around for feedback. The smartest companies I’ve worked with treat those advisors more like co-conspirators—looping them in while ideas are still half-baked. Even a casual “Would this even fly in your world?” text can save months of wasted effort. It’s not formal yet, but that low-friction, ongoing cadence is what builds trust.
Another underused tactic? Taking KOLs out of the usual echo chamber. Instead of just showing them a slide deck, have them walk through your onboarding process, or react to messaging in the context of a real clinical workflow. When they experience it in the environment they actually operate in, you get feedback that’s 10x more actionable. And it signals that you care about more than their name—you care about their insight.
And here’s one more that’s deceptively powerful: co-creating early artifacts. Invite your most aligned advisors to help shape a single line of your positioning, a headline, or a product value statement. It doesn’t just make the messaging better—it builds a sense of ownership. When you eventually ask for a quote or support during a launch, they’re already invested. You're not asking them to sign off on your story—you’re asking them to amplify a story they helped shape.
For more specialized help with growth, check out my firm, Mesh. https://meshagency.com/
Develop Your Go To Market Strategy for Your Real Customer | Shehla Rooney
06 Feb 2026
00:40:20
Built a life-science product that works, but growth stalled? Talk to Bill about diagnosing your commercialization path before you spend years selling to the wrong buyer. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
Physical therapist turned founder Shehla Rooney (GoKnee, https://www.linkedin.com/in/shehlarooney/ ) shares how early success selling to clinicians masked a deeper problem and why realizing the patient was the true buyer changed everything. This podcast focuses on the misfires, mindset shifts, and lessons that reshaped her go-to-market strategy.
00:00 Why growth stalls when founders guess their customer 06:10 Early assumptions and selling to the wrong audience 13:45 The moment customer discovery changed the strategy 21:20 Selling the solution instead of the product 28:40 How listening replaced guessing in go to market decisions 36:05 Applying one marketing lesson across the business 43:30 A simple playbook for founders building real growth
If you’ve built something that works but growth still stalled, this episode will feel uncomfortably familiar.
In Part 1 of this conversation, I talk with physical therapist and GoKnee founder Shehla Rooney about how a breakthrough recovery tool and years of hard work were slowed by one fundamental mistake: selling to the wrong audience.
Shehla walks through the early illusion of traction from her professional network, why marketing to PTs and surgeons felt logical (but wasn’t), and how promoting features instead of outcomes missed what patients actually cared about. She also draws a powerful parallel between bad marketing and bad clinical care, skipping diagnosis and jumping straight to treatment.
Before you spend another dollar on marketing, get clear on who actually converts. DM Bill for the ICP Clarity Worksheet.
#MedTech #DigitalHealth #gotomarketstrategy
How to Bring Pharma to Market by Mastering Brand, Story, and Value | Nara Daubeney
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
Contact Nara Daubeney: https://www.linkedin.com/in/nara-daubeney/ _______________________________ Timestamps: 00:00 Intro 01:31 About Nara Daubeney PhD 04:25 Nara Daubeney’s Motivation 06:35 Demonstrating Value & Phaim Pharma 09:07 Start-up Founders Biggest Mistake 09:44 Nara Daubeney’s Philosophy 09:59 How to Communicate the Value of Your Life Science Company 12:08 How to Empathize with your Customer & Stakeholders 13:53 Identifying Your Target Audience 14:29 Example of Effective Messaging 15:45 Why Websites are Valuable for Life Science Companies 22:25 LinkedIn for Life Science Founders 25:58 Common Life Science Company Positioning and Messaging Mistakes 26:45 Leading with Authenticity in Life Sciences 29:23 Lessons for Life Science Marketing _______________________________
Bringing a brand-new autoimmune therapy to market can feel overwhelmingly complex—especially when you’re juggling scientific rigor, regulatory hurdles, and investor skepticism. Many life science founders struggle to communicate the true value of their innovation, leaving them overlooked in a saturated marketplace.
Imagine finally developing a game-changing treatment only to watch stakeholders shrug because they don’t fully grasp your therapeutic’s transformative potential. Or think about the uphill battle of securing funding when investors can’t see why your product stands out from the rest. Without a clear, compelling brand story and patient-centered messaging, brilliant solutions stay buried.
In this episode of LifeSci Continuum, I speak with Dr. Nara Daubeney—CEO & Co-Founder of Phaim Pharma, surgeon, and biotech executive—about her journey in launching a new autoimmune therapy. She reveals how thoughtful storytelling, audience-focused messaging, and transparent value propositions can attract the right partners and propel clinical success.
From leveraging LinkedIn as a personal brand amplifier to crafting a website that educates and captivates, Dr. Daubeney shares actionable tips for life science entrepreneurs aiming to transform great ideas into real-world therapies.
For those tackling this on their own, consider these tips:
1. Many life science founders focus solely on product development during the early stages, neglecting the power of brand co-creation with their earliest customers. Identify a select group of early adopters—clinicians, researchers, or key opinion leaders—who not only test your solution but also help shape your brand’s narrative. By involving them in refining your brand message, you ensure it resonates with the real-world challenges and aspirations of your target audience. Their buy-in becomes a powerful form of social proof, showcasing authentic advocacy that sets you apart in a crowded marketplace.
2. Embed Scientific Rigor into Every Brand Touchpoint Pro Tip: Consistently Translate Complex Data into Clear, Insightful Narratives. In a field where trust hinges on evidence, your brand must radiate credibility at every turn—yet many life science teams only emphasize data in white papers or scientific conferences. Instead, weave simplified but accurate data-driven insights into marketing materials, pitch decks, and website copy.
3. Design Your Brand for Scalability from Day One Pro Tip: Establish a Modular Framework That Adapts to New Markets and Indications.
For more specialized help with growth, check out my firm, Mesh. https://meshagency.com/
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
Follow Dave: https://www.linkedin.com/in/dave-iannetta/ _______________________________ Timestamps: 00:00 Intro 01:37 Telling a Story that Resonates with Angel Investors 03:23 Case Study 05:40 How to Pitch to Angel Investors 07:15 What Angel Investors Actually Care About 09:10 Building Confidence in Angel Investors _______________________________ In this episode, I sit down again with seasoned marketing executive Dave Iannetta to explore how life science and med device companies can refine their marketing strategy based on where they stand in the fundraising journey.
We kick off by discussing angel investors—often deeply familiar with niche therapeutic areas—who demand more scientific detail and crave confidence in the path to clinical validation. Dave emphasizes that these early backers aren’t just sources of capital; they frequently bring networks and advisory expertise crucial for guiding pre-clinical or early-phase companies. As startups move toward VC or IPO stages, their narrative must evolve—focusing on broader market appeal, long-term viability, and the step-by-step milestones that validate their technology.
Throughout our conversation, we discuss how winning over different investor audiences hinges on adapting your message, demonstrating credibility through thoughtful planning, and clearly outlining your path to commercialization—even if it’s just a high-level preview in the early rounds.
Protips for our viewers:
1. Preemptive Future Staging
Pro Tip: Anticipate the Next Investor’s Questions Before You Even Land the Current Round. Seasoned founders don’t just satisfy the immediate audience; they also layer in hints of what VCs or public-market investors will want to see next—like clinical milestones or commercial frameworks. This helps you stay one step ahead, especially when angels (often experts in your space) start quizzing you on longer-term feasibility.
2. Convert Early Investors into Credibility Amplifiers Pro Tip: Leverage Angel Backers’ Expertise and Networks to Strengthen Your VC or IPO Pitch. The most experienced entrepreneurs recognize that angel investors—many of whom are industry veterans—can serve as potent evangelists to higher-level funders. Make them feel like partners in your success by actively soliciting their input and showcasing how their technical insights informed critical decisions.
3. Craft a Layered Pitch Deck Pro Tip: Design Multiple Versions of Your Deck, Each Calibrated to a Different Fundraising Stage. While angels crave deep scientific detail, VCs favor a clearer path to market, and IPO investors need a simplified “why invest now” narrative. Instead of one-size-fits-all materials, create layered versions that pivot on the fly. This agility signals to prospective investors that you deeply understand what they need to make a confident bet on your company.
For more specialized help with growth, check out my firm, Mesh. https://meshagency.com/
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
How to Tailor Your Messaging to Each Awareness Stage and Accelerate Your Life Science Sales:
“Marketing doesn’t work for us.” Yeah, I hear that all the time.
Honestly though, half the time you’re delivering the wrong message to your buyer at the wrong time.
Impossible you say?
If you’re not delivering the right message at the right stage of your buyers’ awareness, you’re not just missing a sale—you’re actually actively turning prospects off.
With irrelevant messaging, your once-promising leads disengage, trust erodes, and your marketing dollars go to waste.
Don’t tell me… you’ve been pouring months of effort (and dollars) into campaigns, only to see prospects slip away because they either don’t recognize their own problem yet or feel bombarded with brand pitches before understanding why your solution matters.
Each misaligned message is a huge missed opportunity and a step closer to losing market share. In this episode, I break down the five stages of awareness, showing you how to pinpoint exactly where your prospects stand and adjust your messaging so it resonates.
Backed by real-life examples from the life sciences space, these insights will help you deliver precisely what your audience needs, when they need it—turning cold leads into engaged prospects and ultimately driving more conversions.
3 Buyer Awareness Insights for Life Sciences: If you’re serious about growing your company, you really need to be firing on all cylinders (or energy cells?):
Pro Tip #1: Beyond Prospect Personas, Identify Secondary Influencers.
You probably assume the decision-maker is the person in your marketing database, but in life sciences, there’s often a hidden web of KOLs, purchasing committees, or department heads influencing the sale.
By mapping these secondary stakeholders and understanding their unique needs and awareness levels, you can create content paths that reach and resonate with all parties involved—well before a formal buying decision is even on the table.
Pro Tip #2: Use Specific Engagement Cues to Pinpoint Awareness Stage.
Instead of categorizing prospects by broad funnel stages, look for granular behavioral signals—like the types of research papers they download, the complexity of webinar content they consume, or the specificity of their search queries on your site.
These micro-signals can reveal whether they’re just waking up to the problem or already deep in solution exploration. Aligning your messaging based on these nuanced cues helps you deliver precisely the level of technical detail, proof, and urgency they need at that moment.
Better yet, rather than create any and all types of content, focus your limited content creation resources to developing specific content that maps this journey.
Pro Tip #3: Educate the Market Months Before They Know They Have a Problem.
Too many companies focus solely on late-stage branding or solution pitches.
Instead, seed your market months in advance with educational content on emerging challenges and subtle shifts in clinical practice or research methodology.
By the time your prospects realize they have a problem, they’re more than likely to recall your educational content and brand as the one who first put it on their radar. This “pre-awareness” cultivation strategy dramatically shortens the gap between their initial recognition of a problem and seeing your company as a trusted authority with the solution.
For more information on marketing your life sciences brand, check out this blog post: Life Science Marketing: A Comprehensive
How (and Why) to Maintain a Customer-Centric Focus When Planning Your Exit | Glenn Hanner
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
In this episode of LifeSci Continuum, I'm thrilled to reconnect with Glenn Hanner as we dig into a critical challenge that many life science leaders face: the danger of tunnel vision when planning for an exit. Often, the excitement of an exit strategy can overshadow the need to establish a strong foundation and deliver on the promised value to customers. Glenn and I pull from our experiences to discuss how companies can balance long-term strategic goals with immediate customer-centric needs to avoid costly oversights.
Glenn and I explore how companies can get so fixated on the endgame that they neglect the foundational work necessary for sustainable growth, from quality assurance to customer satisfaction. Glenn shares examples from his career, illustrating how failing to invest in fundamentals can derail even the best-laid plans for an IPO or acquisition. This episode is a must-listen for life science professionals aiming to build lasting value, not just chase short-term wins.
For more specialized help with growth, check out my firm, Mesh. https://meshagency.com/
00:00 Intro 01:45 Examples of Investors Affecting a Life Science Company’s Exit Strategy 04:40 Mistakes Caused By Rushing an Exit 06:37 Regulatory Oversight in Med Tech 08:25 Example of a Med Tech Product that was Rushed to Market 09:58 Lessons & Regrets from a Med Tech Marketing Associate 12:34 The Most Important Asset for a Med Tech Start Up Company 13:52 Delivering on the Value Proposition 14:14 Life Science Career Mistakes & Regrets 15:20 Examples of a Good Exit Strategy 17:00 The Ins & Outs of Life Science Regulation 18:56 The Value of Good Leadership 20:35 Why Marketing Function is Different in Every Industry 22:05 Alignment Between Marketing & Business Goals 24:42 A Book that Every Marker Should Read - Positioning by Al Ries & Jack Trout 25:24 Psychology & Bad Landing Pages 26:07 Storytelling 26:55 Your Customer’s Needs
Life Science Marketing Agencies Exposed: Top Secrets Revealed | Marc Frechette
This is the chat life science marketing agencies don’t want clients to watch.
In this episode of LifeSci Continuum, I'm joined again by Marc Frechette.
In this episode, Marc and I pull back the curtain on life science digital marketing agencies. Both of us have been on both sides: we've hired agencies as clients and worked inside them, so we know the dirt.
We dig deep into common pitfalls agencies face, and by extension, their clients, like lack of actionable insights in reports, misunderstood keyword strategies that drive clicks but not leads, and vague campaign objectives. We reveal how agencies often focus on vanity metrics instead of meaningful results, and why their hundreds-page reports are often impossible to act on.
Our conversation goes beyond the surface, addressing how agencies miss the mark on critical analysis, how SEO and ads are often poorly executed, and the frustrations clients face with vague, hollow campaign promises. But we don’t just stop there. We also discuss what companies can do to get big wins, what to demand from your agency, and how to actually turn your digital marketing investment into tangible growth.
This is a candid, no-holds-barred conversation about the real issues that plague life sciences marketing, and it’s packed with practical advice you can start using today. If you’ve ever felt like your agency was missing the mark or wondered how to drive real ROI from your marketing campaigns, this episode is for you.
Establishing metrics and KPIs right from the start is critical because they provide a clear framework for measuring success and guiding strategy. For life science startups, these metrics ensure that every decision—whether it’s marketing, product development, or customer engagement—is data-driven, allowing you to assess what’s working and pivot quickly if needed.
For life science founders, the most important awareness metrics should directly impact your company's strategic goals and align with the complexity of the industry. Here’s a deep dive into critical metrics:
Number of Cold Prospects Warmed Up for Retargeting: Measure how many cold social media prospects you’ve engaged through educational or entertaining content and can now target with remarketing efforts.
Qualified Leads Generated: Track high-quality leads from key life science decision-makers, not just volume.
Referral Sources from Scientific Communities: Assess awareness driven by reputable scientific publications and communities.
Content Engagement by Key Decision-Makers: Monitor downloads of technical resources by your target audience.
Organic Search Traffic from High-Intent Keywords: Ensure you rank for specific, high-intent scientific keywords relevant to your products.
Scientific Citations/Backlinks from Reputable Journals: Measure authority-building citations and backlinks from trusted journals.
As a fractional CMO in the life sciences, I can help you establish, track, and optimize the right metrics and KPIs that align with your business objectives. This includes defining what success looks like for your specific stage of growth, whether it's early lead generation, nurturing prospects, or moving toward commercialization. I'll ensure that your marketing efforts are measured using data-driven insights, helping to identify opportunities, optimize campaigns, and make informed decisions to accelerate growth and ROI while minimizing wasteful efforts.
For more specialized help with growth, check out my firm, Mesh. https://meshagency.com/
Get More Leads with Customer Value Journey Mapping | Kathleen Mitchell
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
In this episode of LifeSci Continuum, I'm joined again by Kathleen Mitchell as we dive into B2B content mapping and how to align your content strategy with overall business objectives. We explore the importance of customer-centric campaigns, from creating content that resonates with target audiences to nurturing leads through content refreshes and retargeting efforts.
Kathleen also shares insights on understanding your customer’s value journey, and how this knowledge can enhance content marketing, ensuring your efforts are continuously engaging and relevant.
Are you struggling to make your content marketing efforts truly impactful? Maybe you've been creating tons of blog posts, white papers, or emails but still aren’t seeing the engagement or conversions you expected. Chances are, you're missing a critical step—connecting your content with your customer's actual journey. Without a clear strategy, even great content can fall flat, failing to move your prospects through the sales funnel. That’s where content mapping comes in.
Content mapping aligns your content with the stages of your customer value journey, ensuring that your messaging not only attracts attention but also nurtures leads and builds trust along the way. See, you might be producing relevant content, but is it reaching your audience at the right time? Are you providing the answers they need when they are looking for them? That’s where the real magic happens—targeted, timely content.
Today, content quickly becomes stale. A white paper from a year ago, no matter how in-depth or well-researched, may no longer hold the attention of your audience. Trends evolve, new competitors emerge, and what was once a high-performing blog post may now struggle to rank in search results. With content mapping, you continuously refresh it, optimizing keywords and repurposing it for different stages of your buyer's journey, ensuring it stays relevant and engaging.
Your content strategy should guide prospects toward a purchasing decision. With a well-constructed content map, you can plan specific assets for the awareness stage—where your audience first realizes they have a problem—through to the consideration stage, where they evaluate different solutions, and finally, the decision stage, where you help them feel confident in choosing your product or service.
More importantly, content mapping allows for retargeting. It ensures that if a potential customer leaves your site after consuming a piece of content, you can continue to engage with them across platforms, pulling them back in with tailored follow-ups that address their evolving needs.
The benefits go beyond better engagement. When you align content with business goals, you’re creating a system that not only nurtures leads but moves them forward through the pipeline with precision. Whether you're educating potential customers, addressing their pain points, or reinforcing your solution’s value, content mapping provides structure and clarity to your strategy.
Stop wasting time on random acts of content creation. Get strategic with content mapping and start turning your content into a powerful lead-nurturing machine.
For more specialized help with growth, check out my firm, Mesh. https://meshagency.com/
How to Start a Life Science Company: Busting 3 New Founder Misconceptions | Karthik Ramachandran
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
In this episode of LifeSci Continuum, I'm joined by Karthik Ramachandran, a Biotech Executive and Co-Founder of Likarda, to tackle three major misconceptions that new life science founders face.
We examine critical challenges like customer acquisition, the “build it and they will come” fallacy, and understanding the information customers need to make high-stakes purchasing decisions. Karthik shares insights from his journey as a scientist turned entrepreneur, offering valuable advice on business planning, product development, and navigating the complex world of biotech startups.
The "Build It and They Will Come" Fallacy
The "build it and they will come" fallacy is the mistaken belief that simply creating a great product will automatically attract customers. Many life science startups fall into this trap because they focus heavily on product development and assume that their innovative solution will naturally generate interest and sales.
However, without a well-thought-out marketing, sales, and customer acquisition strategy, even groundbreaking products struggle to gain traction. In life sciences, this is particularly problematic because the markets are niche, highly competitive, and require deep customer education and engagement for success.
To learn more about the Build it and They Will Come fallacy or myth, what contributes to it, and how you can overcome it, check out my blog: https://meshagency.com/life-sciences-misconceptions-the-build-it-and-they-will-come-fallacy-a-myth-busted/
Scientists, clinicians, and engineers often fall prey to the "build it and they will come" fallacy because they are trained to focus on solving technical problems and developing innovative solutions. They assume that if the product is scientifically sound or technically advanced, it will naturally attract interest.
However, they may underestimate the importance of customer education, marketing, and the complexities of market adoption. Additionally, their expertise in research and development can lead to a bias toward the product’s capabilities rather than the customer’s needs or market readiness.
Here are three things life science founders can do to avoid or overcome the "build it and they will come" fallacy: 1. Develop a Customer-Centric Strategy Early: Engage potential customers from the start through interviews, focus groups, or surveys to understand their needs and ensure product-market fit. 2. Create a Go-to-Market Plan: Build a marketing and sales strategy that includes how to reach customers, educate them, and create demand for the product. 3. Prioritize Partnerships and Networking: Collaborate with key opinion leaders (KOLs), healthcare institutions, and industry influencers to build credibility and accelerate adoption.
For more specialized help with growing your life science company, check out my firm, Mesh Agency. https://meshagency.com/
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
In this episode of LifeSci Continuum, I’m joined by Glenn Hanner, FCMO and experienced marketing leader in the industry to explore how life sciences companies can tap into the power of storytelling and the voice of the customer to create product differentiation and develop new market niches.
Glenn shares his insights on turning customer feedback into compelling marketing messages, building strong product positioning, and crafting stories that resonate emotionally with end-users. From copywriting to crafting a go-to-market strategy, this episode covers critical aspects of successful life sciences marketing.
He discusses how leveraging the voice of the customer is pivotal in driving product differentiation and creating new market opportunities in life sciences. By deeply understanding customer pain points and needs, companies can tailor their marketing strategies to solve specific problems, offering unique value.
Glenn also emphasizes the importance of using emotionally engaging storytelling and clear, concise copywriting to communicate this value, ensuring your product resonates with both technical and non-technical audiences. Additionally, we dive into the process of carving out new niches by listening to customers and creating solutions that fill unmet needs. This episode offers practical guidance on how to stand out in a crowded market while keeping the customer at the center of your strategy.
Why are we focusing on voice of customer?
Technical and science-based founders in life sciences often overlook the voice of customer because they tend to approach product development from a problem-solving mindset. They assume that the issues they perceive will be equally apparent and valued by the market. This leads them to believe that customers will automatically recognize the value of their innovation, especially when it solves a technical or scientific challenge. However, customers may not always share the same priorities, and without direct feedback, founders risk creating products that don’t align with real-world needs or user preferences. Additionally, these founders often undervalue the importance of marketing and customer insight, assuming that the superior functionality of their solution will drive demand on its own.
This disconnect stems from a belief that a product’s technical brilliance will lead to adoption, but in reality, the customer’s experience and perceived value often dictate success. Listening to customers helps align product features, messaging, and benefits with what matters most to the market, ensuring the solution is seen as essential and not just an interesting innovation.
Here are three quick tips to work around the tendency of technical founders to overlook the voice of the customer: 1. Engage Early with End Users: Involve potential customers from the product ideation stage through user surveys, interviews, or focus groups. Their input will reveal whether the perceived problem and solution resonate with them. 2. Create Customer Personas: Develop detailed customer personas based on real data to ensure the product and messaging align with the actual needs and priorities of the target audience. 3. Iterate Based on Feedback: Implement feedback loops to regularly refine product features, positioning, and messaging based on customer reactions and market demand.
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
Follow Marc: https://www.linkedin.com/in/digitalmktggeek/ About Marc: Marc is a veteran digital marketing and communications professional with a proven record in medical devices, consumer goods, and industries ranging from industrial robotics to liquor and wine. He is shamelessly scientific & unapologetically passionate.
Using Omnichannel Marketing to Launch Your Digital Health Product | Kathleen Mitchell
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
Follow Kathleen Mitchell: https://www.linkedin.com/in/canadiankate/ About Kathleen: She is a Strategic marketing executive with 20+ years of experience leading growth and innovation across start-ups, nonprofit associations, mid-market companies, and global enterprises.
In this episode, I sit down with Kathleen Mitchell, a talented senior marketing leader, to explore the launch of a healthcare virtual pharmacy app in the Canadian market. We dive deep into omnichannel marketing strategies, discussing how to be ubiquitous and make an impact using all media channels. From social media to paid media to account-based marketing (ABM), learn how to master marketing in healthcare and maximize visibility in a competitive space.
This episode is particularly valuable for life sciences companies launching new products because it explores how to effectively reach a diverse and specialized audience. The strategies Kathleen shares—are critical for creating impactful, targeted campaigns that drive awareness and adoption. Life sciences companies can learn how to market their products in a highly competitive market, ensuring they're visible across all relevant channels and engaging key decision-makers with precision and relevance.
How to Build a Winning Life Science Sales Team | Pete Tortorelli
21 Jan 2026
00:38:00
Need go-to-market that sales actually uses? Book a 20-minute Fractional CMO consultation with Bill to align marketing, VOC, and field execution—so reps stop “pushing” and start solving.
- Visit https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/ to learn more.
Pete Tortorelli (GM/Managing Director, Revvity) breaks down how to build life science sales teams that scientists actually trust. We cover application-specific selling, channel orchestration, hiring for integrity and curiosity, and why the best reps sometimes refer business to competitors.
Connect with Pete: linkedin.com/in/ptortorelli
00:00 Why life science sales fails without market awareness 00:10 Building sales teams scientists actually trust 01:55 From accidental sales teams to intentional design 05:07 How to sell to scientists without “selling” 07:43 Do life science sales reps need a science background 09:58 Tracking trends that reshape lab workflows 11:41 Selling by solving real lab pain points 17:21 Why integrity beats short-term revenue 27:39 When sales drives product innovation
Life science buyers aren’t shopping for hype; they’re validating hypotheses. Pete Tortorelli led Omni through growth and acquisition and now runs the business inside Revvity.
In this episode, he lays out how to build a sales model scientists respect: application-specific proof, honest discovery, and rigorous support from an app's “cavalry.”
We get tactical: how to use interrogative selling to find true constraints (budget, staffing, SOPs), when to cut bait, and why referring a misfit project to a competitor can earn long-term trust. On team-building, Pete favors integrity and curiosity over perfect CVs, then surrounds reps with fast, accurate answers.
Finally, we look forward. Your advantage isn’t a louder pitch; it’s a tighter proof.
3 Secrets to add to Pete’s Sales Model
1. Sales is your fastest learning loop — faster than product, faster than marketing. In life science, sales isn’t just about closing deals; it’s about learning in real time. If you’re paying attention, sales will tell you things your dashboards never will — before you’ve spent months building the wrong thing.
The founders who win are the ones who treat sales as an intelligence engine, not just a revenue function. They expect their sales motion to surface insight weekly, not quarterly. If your sales conversations aren’t teaching you something new about your market regularly, that’s a systems problem.
2. Trust isn’t built by good intentions — it’s built by systems that hold up under pressure. Everyone says they value integrity. That’s easy when things are going well. The real test comes when a rep is behind quota, a quarter is tight, or a big logo is dangling just out of reach. Trust doesn’t survive on values alone — it survives on structure.
Founders have to design systems that make honesty the default, even when it’s inconvenient. If you’re relying on “good people” without guardrails, you’re putting your reputation at risk without realizing it.
3. The real constraint in modern labs isn’t budget — it’s cognitive load. It’s tempting to assume price is the blocker, but more often it’s mental bandwidth. Labs are understaffed, overworked, and drowning in complexity.
The products that win aren’t always the most powerful; they’re the ones that simplify life. Less explaining to a boss or a collaborator. If your product asks someone to think harder, it needs to replace something else entirely — otherwise it just adds friction, no matter how impressive it is on paper.
Follow Life Sci Continuum for real-world commercialization lessons from operators who’ve built, scaled, and learned the hard way.
Visit https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/ to learn more.
#LifeScienceSales #MedTechGTM #CommercialE
Tackling The Biggest Life Science Product Marketing Challenges | Bill Schick
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
Follow Russ on LinkedIn: https://www.linkedin.com/in/russouellette/ Russ's Podcast: https://www.youtube.com/@RussOuellette @RussOuellette
In this episode, I’m joined by Dr. Russ Ouellette, founder of Sojourn Partners, an executive coaching and leadership firm. We explore how to work with highly intelligent individuals, build strong leadership teams, and transform top contributors into effective leaders. With over 10,000 people coached, Dr. Ouellette shares key insights into building a culture of trust and accountability. Whether you're leading a team of bright minds or developing leadership within your organization, this episode offers practical strategies to help you succeed.
Dr. Ouellette offers powerful insights into creating a leadership culture in your organization, especially when working with smart, high-performing individuals. He explains why trust and accountability are the foundation of strong teams and how even the brightest contributors can struggle to transition into leadership roles without the right mentoring.
For life sciences companies, where innovation often depends on collaborative work across diverse teams, these lessons are key and often missed. Whether you're scaling a startup or running a large enterprise, fostering leadership at all levels helps ensure sustainable growth, adaptability, and success in competitive markets. Dr. Ouellette’s practical advice will help life science companies of all sizes build resilient leadership that drives both individual and organizational success.
In this episode, I’m joined by Kate French to explore the critical process of business case development in the life sciences industry. Whether you're conceptualizing a new product, enhancing an existing feature, or considering your next acquisition, developing a solid business case is the first essential step.
Kate, with her wealth of experience, shares insights on how to build business cases from the ground up—both organically for product development and inorganically for acquisitions. This episode is packed with practical tips for product managers and marketers working to secure investment and drive growth.
Kate breaks down the fundamentals of business case development, explaining its importance in securing internal investment for new products, features, or acquisitions. She shares her experiences in navigating the delicate balance between innovation and market needs, including how to justify or challenge ideas from R&D.
This episode offers practical advice for life sciences professionals on how to effectively present a business case that aligns with user demand and business objectives, making it an invaluable guide for driving product and company growth.
Forecasting your Exit (as a Life Science Company) | Dave Iannetta
22 Aug 2024
00:22:27
When it comes to product launches, we tend to hyperfocus on just simply getting everything to launch and we tend to leave the exit strategy to the end. On this episode of LifeSci Continuum, we are joined by David Iannetta as we learn that it is truly never too early to start preparing for your exit.
Preparing for your Life Science Product Launch | Christi Unger
22 Aug 2024
00:30:37
Launching a product is a rollercoaster for product managers and marketers. But jumping in right before the finish line is a different type of ride. In this episode, we are joined by Christi Unger as we discuss her experience launching life-science products and the lessons she learned.
The Keys for Building High Performance Life Science Teams | Kate French
22 Aug 2024
00:22:21
Without two important team traits, your team might be missing their mark. On this week's episode, Kate French joins us to talk about her experience working with engineering and what goes into building effective, high-performing teams in your life sciences company.
Welcome to LifeSci Continuum with Bill Schick | Podcast Introduction
04 Aug 2024
00:02:14
Kicking off the LifeSci Continuum, we are going to cover almost every aspect of Commercialization and product life cycle stage. From Launch to Exit, we go deep with expert interviews, tips, shortcuts, and best practices to help you level up.
Video Podcast: https://www.youtube.com/@BillSchickFCMO Audio Podcast: https://www.buzzsprout.com/2380430
Go Above & Beyond with Your Next Medical Device Launch (or Exit) | David Iannetta
04 Aug 2024
00:46:56
You might be thinking about highlighting the features and benefits of your medical device. Well, David Iannetta joins us to talk about how looking past the status quo could be the X-Factor for your next Product Launch (or Exit).
Product Management Basics (for Life Science Companies) | Jim Dembkoski
04 Aug 2024
00:59:37
On this episode, we are joined by Jim Dembkoski who is bringing 15 years of product management advice to the table. Join us as we discuss how Jim got into Product Management and the key lessons he learned along the way.
To Scale: Focus on Your Customer Needs | Mike Pyne
21 Jan 2026
00:43:18
Need product-market fit and pipeline fast? Book a 30-min MESH sprint audit with Bill. https://meshagency.com/lets-connect/
In this episode, Founder/CEO Mike Pyne, Medoh Health shares how he turned short-form video + AI into a doctor-specific knowledge platform that saves hours of repetitive patient Q&A. We cover testing in the clinic (not just the cloud), communicating by text vs. QR, when to hire (and not hire) sales, and the founder mindset for speed without sacrificing quality.
Connect with Mike: https://www.linkedin.com/in/michael-d-pyne-627864136/
00:00 – Why medical information fails patients 04:15 – What patients actually want from medical content 08:30 – Building the “TikTok for medical information” 12:45 – How to earn trust in patient education 17:20 – Using patient feedback to improve healthcare content 21:45 – What keeps patients engaged with medical information 26:10 – Why short-form medical education works 30:35 – Balancing accuracy, speed, and attention in healthcare 35:10 – Scaling a patient-first medical platform 39:20 – Lessons for building patient-centered health products
What happens when you mix short-form video, a pile of patient questions, and a founder obsessed with real-world feedback? Mike Pyne, Founder & CEO of Medoh Health, walks us through his journey from medtech sales and marketing at Smith+Nephew to building a platform that digitizes a doctor’s knowledge and delivers it to patients 24/7.
Mike kept hearing the same thing in clinics: doctors repeat themselves all day and patients still leave with uncertainty. The winning combo: doctor-specific short videos plus AI that answers only from the doctor’s own content and documents.
We dig into building in the clinic, not just in the cloud: direct patient interviews, text-first delivery (ditch the QR friction), and shipping fast while staying safe. Mike shares the hiring calculus (why you shouldn’t add sales until PMF), how to delegate without losing speed, and how the phrase “TikTok for medical info” unlocked stakeholder understanding. If you’re a founder in healthtech or any regulated space, this is a masterclass in iterative learning and pragmatic velocity.
Three Practical Pro Tips
1. Design for the moment your customer stops paying attention One thing that shows up between the lines of Mike’s story is this uncomfortable truth: momentum stalls because life moves on. Patients forget. Clinicians get pulled into the next room. Founders assume adoption happens just because something is valuable. It doesn’t.
As a founder, your real design challenge is what happens after the conversation ends. The teams that win plan explicitly for that drop. If your product only works when people are focused, it won’t survive contact with reality.
2. Separate “people like it” from “people will actually use it.” Founders get great at collecting positive feedback. “This is awesome.” “I’d totally use this.” “This would save us so much time.” And then… nothing changes. No behavior shift. No habit formation. No adoption.
They miss the mark because they’re confusing agreement with integration. The hard work lives in understanding how something fits into a real workflow, not an ideal one. Who owns it when the founder isn’t around?
3. Treat distribution as a trust decision, not a tech decision Mike’s QR-code lesson is a classic founder trap: building something logical instead of something human. People adopt tools because they arrive through channels they already trust. No one actually cares about elegance.
As a founder, it’s worth stepping back and asking: If adoption requires users to learn a new behavior and trust a new channel at the same time, you’ve doubled the risk.
Book a 30-min MESH sprint audit with Bill. https://meshagency.com/lets-connect/
#DigitalHealth #MedTechMarketing #ProductMarke
The Founder’s Playbook for Med Device Engineering | Tim Looney
29 Dec 2025
00:34:49
Have the engineering plan but need the market plan? Hire a Fractional CMO to de-risk launch and accelerate adoption.
Book a strategy call. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
President/CEO Tim Looney (Northeast Biomedical) breaks down the engineering plan founders actually need (DHF, phased reviews, and right-sized documentation) to move faster without tripping FDA/CE. We cover startup blind spots, big-company constraints, and how to “do it right once” so you don’t pay for DHF remediation later.
00:00 Why med device engineering fails 00:16 Who is Tim Looney 03:04 What founders miss in early engineering 06:11 Why the FDA rejects “it’s all in my head” 08:13 Hidden tests and documentation you must plan for 12:24 Move fast the right way 15:53 How phased engineering speeds up approvals 20:23 How to avoid costly founder mistakes 24:44 Why the system blocks unprepared founders 27:11 Case study on fast clearance done correctly
In medtech, “move fast and break things” breaks people. Tim Looney leads Northeast Biomedical, a product development and contract manufacturing firm that lives where speed meets compliance. In this episode, Tim explains the engineering plan most founders skip: phase-gated reviews, checklists that prevent “oops” moments at submission, and documentation that’s lean early but complete enough to avoid costly DHF remediation. We unpack startup blind spots (biocompatibility, shelf-life, packaging, verification), how larger companies get stuck in resource bottlenecks, and why the fastest path to clearance is often meticulous—just not bloated. Tim also shares a class-III European dossier story that moved in weeks because the package was complete, plus practical guidance for early founders on prototypes, notebooks, and IP strategy. If you’re building the next device, this conversation is your map to “right the first time.”
The IPO Playbook: Evidence, Agility, and Investor Trust | David Iannetta
29 Dec 2025
00:16:12
Not seeing investor-grade pipeline from your science? Bill is the Fractional CMO for complex medtech & life-sci GTM. Book a 20-min diagnostic. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
• Connect with Dave Iannetta on LinkedIn: https://www.linkedin.com/in/dave-iannetta/ • Subscribe to Bill Schick’s Newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7154518390324281344
00:00 The IPO Playbook 02:30 Being Unprepared for IPO 04:30 Data & Market Validation 06:05 FDA Changes in 2025 09:27 Tips for Creating an IPO Deck 13:23 Messaging for IPO
About this episode: Early funding rounds reward vision, but the IPO process rewards verification. David joins me again to walk through the journey from institutional capital to public offering and shows how every assumption that once lived in a slide note must now survive legal discovery. He recalls deals that stalled because total-addressable-market figures lacked primary sources and others that crumbled when an FDA setback forced a last-minute pivot the team could not explain. His core message: a marketer’s real job at this level is to translate complex clinical value into a dollar-based opportunity that bankers can model and retail investors can grasp in two sentences.
Three IPO Musts: 1. Treat market sizing the way a biostatistician treats a primary endpoint. Start with bottom-up data such as procedure volumes from CMS, epidemiology registries, or detailed purchase-order pulls from group-purchasing organizations. Build the model cell by cell so any analyst can trace volume, price, and adoption-rate assumptions back to a public document or a signed customer quote. Keep totals in three buckets—total addressable market, serviceable market, and realistically obtainable share—so you are never accused of using a single inflated figure. A grounded model not only survives diligence but also shapes banker sentiment; if you claim a four-billion-dollar market and the underwriters later pin it at one, you can lose half your valuation before the first road-show slide appears.
2. Create a living archive for every assumption that feeds your financials. Store PDFs of journal articles, invoices that justify cost inputs, raw spreadsheets, and even audio transcripts of expert interviews in a well-indexed data room. Each time a figure changes—perhaps because new coding data arrive or the FDA requests a larger trial—update the archive and note the version in your working deck. Bankers, lawyers, and syndicate analysts will audit each cell in your spreadsheet against its original source; if you have to scramble for proof after the S-1 is filed you will burn weeks, pay extra legal fees, and lose the momentum that makes an IPO window attractive in the first place.
3. Build your narrative as a living document that flexes with every regulatory update or clinical read-out. Investors do not punish a company for hitting a speed bump; they punish it for ignoring the bump or pretending it did not happen. Hold regular “story scrubs” where marketing, clinical, and finance teams rewrite the pitch deck in light of the latest data, resize the market if endpoints shift, and script a clear path forward. Practising this iterative storytelling prevents the deer-in-the-headlights moment when a diligence call surfaces new questions and shows investors that the team can navigate uncertainty as confidently as it develops science.
For more specialized help with growth, check out my firm, Mesh. https://meshagency.com/
#IPOReady #LifeScienceMarketing #MarketSizing
How to Launch a Successful Healthcare App | Peter Attia
17 Dec 2025
00:34:00
Ready to launch faster? A fractional CMO can help. Talk to MESH. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
Founder Peter Attia built Family Vitals, an iOS app that helps families securely organize, collaborate on, and understand their medical records—without reinventing a risky data stack. We cover validation before code, scoping to ship, leveraging Apple Health, surviving App Store review, and why security is the feature. Great listen for solo founders and health-tech teams.
Peter Attia, founder of Family Vitals: https://www.linkedin.com/in/peter-attia-90945052/ Family Vitals: https://www.familyvitals.com/
00:00 Why this app began, family pain to product idea 02:14 What Family Vitals does (iOS, collaboration, AI) 04:18 Solo founder build, whiteboard to design to code with AI 07:25 Why iOS first, cost, HIPAA, and not hosting data 10:02 MVP focus and early validation (surveys, willingness to pay) 15:10 Tech surprises and Apple review realities 19:34 Platform leverage, Apple Health vs rebuilding integrations 20:11 What he would do differently, talk to devs, prelaunch list, outsource brand 28:35 Setbacks and plan B during review 30:20 Security and trust, document everything, treat data as core
Peter, a software engineer with a data/analytics background, built Family Vitals, an iOS app that lets families securely store, organize, and collaborate on medical records, notes, images, and lab reports—while pulling data via Apple Health from thousands of clinics and hospitals. He explains why he chose iOS first (security posture, cost, infrastructure leverage), how AI sped up 30–40% of the busywork (but not the architecture), and why scoping ruthlessly was the only way to ship.
We dig into market validation (conversations + survey with the “sandwich generation”), navigating a multi-month App Store review for medical data, and the choice to use the platform’s rails rather than roll his own HIPAA-heavy backend. Peter shares what he’d change—start lead collection months earlier and partner on branding/positioning sooner—and leaves builders with a clear mantra: validate early, document security, and stack your work so launch momentum isn’t an accident.
3 Founder Moves Peter Used to Ship Faster
Tip 1 — Validate before you code (and build a waitlist): Run 15–25 quick interviews with your target “family manager” persona + a lightweight 4–6 question survey to size the pain and test willingness to pay. Stand up a 1-page teaser + email capture and drive $10–$20/day traffic for two weeks. Green-light if you see ≥50–60% positive intent, ≥20% signup rate, and clear top-5 “must-have” features. Parking-lot the rest for later.
Tip 2 — Ruthless scope via platform leverage: Pick ONE platform that removes risk. For health data, iOS first can unlock HealthKit/Apple Health connectivity, native security rails, and faster build loops. Design your MVP around the smallest end-to-end journey (e.g., import record → add note → share with family) and trim anything that slows App Review.
Tip 3 — Security-first from Day 0 (document everything): Assume regulators, platforms, and partners will ask “how do you protect PHI?” Create a living security pack: data-flow diagram, storage decisions (avoid holding what you don’t need), access controls, audit trails, breach response, and privacy policy. Align features to what platforms will approve now (text-only chat before advanced agents, etc.). This prep shortens review cycles and builds user trust you can market—screenshots of your security posture, not just UI.
Need go-to-market firepower? Book MESH. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
#HealthTech #FounderJourney #DigitalHealth
The 3 Branding Mistakes That Stop Product Growth | Jim Macleod
22 Sep 2025
00:47:12
Find out how a Fractional CMO can get the right questions answered from the right audience. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/ - Connect with Bill https://www.linkedin.com/in/founderandcdo/
Jim MacLeod Designer-turned-marketer, brand systems builder, and author of The Visual Marketer—a field guide that translates design fundamentals for marketers and founders. - Connect with Jim MacLeod: https://www.linkedin.com/in/jimmacleod/ - Jim’s Book: https://book.jimmacleod.com/
Struggling to make great tech look inevitable? Bring in MESH as your fractional CMO to turn brand, web, and product storytelling into qualified pipeline.
Designer-turned-full-stack marketer Jim MacLeod breaks down why “good enough” visuals stall growth, how he led a 90-day rebrand without losing brand equity, and the small design choices that decide whether your product gets tried…or ignored.
00:00 Intro — brand fragmentation & growth roadblocks 01:12 Meet Jim Macleod — design, marketing & brand systems 04:17 Case study — 90-day rebrand under Apple-style deadlines 08:27 Why keep the purple? Modernizing without losing equity 12:25 Outdated design vs. innovative tech — fixing the disconnect 16:08 Sales decks & storytelling — shaping the brand narrative 18:10 Customer support as brand — protecting what matters in acquisitions 20:32 Bridging design & marketing — lessons from The Visual Marketer 25:00 Three essentials founders can’t DIY: logo, colors, consistency 31:00 Why first impressions matter — design as trust and credibility 35:09 Trade shows & booth design — why presentation drives traffic 39:10 When to invest in brand — moving beyond referrals 42:12 Copy vs. design — which comes first, and why both matter 45:57 Final thoughts, book link & wrap-up
Founders swear “the tech sells itself.” Buyers don’t. In this episode, Jim MacLeod shows how small visual decisions snowball into trust, attention, and adoption. He walks us through a compressed 90-day rebrand, explaining why his team kept the legacy color (because the market already mapped it to credibility) while modernizing everything around it.
Brand Swagger: Jim’s 3 No-BS Design Wins
- 1) Codify your visual system—once. Stop “designing from scratch” every asset. Build a one-page brand kit that nails your type hierarchy, color roles, spacing grid, icon style, motion rules, and image treatment (e.g., duotone, depth, lighting). Turn those into tokens in your CMS/Slide master so the choices are baked in. Result: faster production, fewer off-brand detours, and a look that’s unmistakably you across web, decks, UI, and booths.
- 2) Color with intent, not taste. Pick an ownable anchor color (distinct in your category), pair it with two neutrals for clinical credibility, and reserve one accent for calls-to-action and data highlights. Pressure test it in the wild: accessibility contrast, print vs. screen, scrubs/OR lighting, tradeshow LEDs, and dark mode. If it fails anywhere your buyers live, it’s not your color system—it’s a liability.
- 3) Design the first impression you can’t afford to miss. Prioritize the touchpoints that actually sell: homepage hero, product shell/packaging, sales deck front half, and 10×10 tradeshow booth. Make them story-led (problem → outcome → proof), ruthless on clarity (one idea per screen), and visually scannable at six feet. Then measure like a grown-up: booth dwell time, deck completion rate, hero click-through, and demo requests tied to those assets. If it doesn’t move pipeline, it’s just decoration.
For more specialized help with growth, check out my firm, Mesh. https://meshagency.com/
#DesignThatSells #MedTechMarketing #FractionalCMO
Why Products Stall (use VOC to Fix It) | Dave Kern
17 Sep 2025
00:47:51
Find out how a Fractional CMO can get the right questions answered from the right audience. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/
Connect with Bill https://www.linkedin.com/in/founderandcdo/
Connect with Dave Kern https://www.linkedin.com/in/david-kern-dkny/
Product stalls aren’t engineering problems—they’re listening problems. Dave Kern joins us to unpack practical Voice of Customer (VOC), why brand awareness matters before the sales call, and simple, low-cost ways to validate direction without bias.
00:00 Brand awareness & Why VOC isn’t optional 01:36 Meet David Kern — data over opinions 05:15 VOC 101: quant vs. qual, why it matters 07:25 Case study: “our users aren’t on social”… until the data says they are 12:49 From low awareness to lift: education-first digital done right 15:25 What sales wishes prospects knew before the meeting 18:10 Simplify the science; visuals that help, not distract 22:53 Getting buy-in: start small → scale VOC 26:09 Selling into systems: trust, advocates & avoiding “me-too” 31:08 Quick wins: tap networks + one-question polls 40:39 Segmentation, hidden influencers & avoiding bias 47:31 Wrap-up
Too many teams “build it and they will come.”
They won’t.
Dave Kern breaks down how Voice of Customer turns foggy assumptions into crisp direction—so marketing educates, sales accelerates, and product lands. We talk brand warm-up (why strangers won’t buy), short educational content that stops the scroll, and how to run quick, bias-resistant validation without a six-figure research budget. Dave shares practical patterns: use social polls to test beliefs fast, ask the Five Whys to get past surface answers, and interview the people who didn’t buy to find the real friction. We also cover avoiding KOL-only echo chambers, sizing the true reachable audience, and framing VOC for execs who want outcomes, not research theater.
Stop Guessing, Start Hearing: Dave Kern’s 3 VoC Power Plays Tip 1 — Pre-commit to the decision your question will drive: Before you draft a survey or book interviews, list the 3–5 product/marketing decisions you’ll make based on the answers (e.g., “If ≥60% say X, we build Feature A first”). Use a tight, 10-question cap, apply the Five Whys to 2–3 core items, and split audiences (KOLs vs. everyday users). Aim for a fast N=20 “sanity pass” via short calls + one-click social polls; anonymize responses so titles don’t sway outcomes. Tip 2 — Warm the market while you listen (90-day runway): Run education-first content (problem → science → implication) in paid/organic social to the exact audience you’re interviewing. Ask sales, “What do you wish they knew before you walk in?” and turn that into 60–120s explainers. Tag everything with UTMs, equip reps with the same assets, and track leading indicators (video completions, return visitors, branded search) so brand lift and VoC learnings compound. Tip 3 — Design out bias in the room and the sample: Don’t let KOLs speak for the market. Include “no” and “lost” accounts, set a quota for late-majority users, and add 3–5 disconfirming interviews. In workshops use silent ideation → dot-vote to equalize voices, time-box discussion, and name a single decision-maker with a decision deadline. Document assumptions in a one-pager and “red team” them before you spend.
Burning budget on noise? Audit with an FCMO → keep what works. https://meshagency.com/fcmo-fractional-cmo-fractional-marketing/